FDA To Speed Up Review Of Roche Tecentriq As Immunotherapy Treatment For Bladder Cancer – Tech Times
Tech Times |
FDA To Speed Up Review Of Roche Tecentriq As Immunotherapy Treatment For Bladder Cancer
Tech Times Swiss pharmaceutical company Roche has announced that U.S. health regulators have agreed to grant priority review to its Tecentriq immunotherapy treatment for a type of bladder cancer. In a statement, the drug company said that the U.S. Food and Drug … FDA Grants Genentech's Cancer Immunotherapy TECENTRIQ … FDA speeds up review of Roche's bladder cancer drug FDA Approval To Roche's Tecentriq: Now Treat the Bladder Cancer |
